GARDP global network
Based in Geneva, GARDP is committed to carrying out antibiotic R&D in regions heavily affected by drug resistance and to ensuring that approved treatments in our portfolio reach patients in those regions. With our co-founder and alliance partner DNDi, we have a cost-efficient global network.
GARDP teams are currently hosted in several locations worldwide through DNDi, including Brazil, India, Japan and Thailand. To advance engagement in Africa, an independent collaborative entity known as DNDi GARDP Southern Africa was established in South Africa in 2018. GARDP North America Inc., also an independent organization, was established in 2021. We will continue to increase our presence in key geographies which support our clinical trials and access activities.
GARDP’s team is strategically located to facilitate partnerships with research and healthcare institutions in India, South Africa, and other countries that are heavily affected by drug resistance.
GARDP collaborates with R&D institutions around the world, drawing on local expertise and skills and expanding local capacity as needed for current and future clinical research.
An alliance agreement with DNDi enables GARDP to support its team in key regions throughout the world without significant increases in overhead costs.
GARDP Global Network
GARDP Foundation
Set up as an independent not-for-profit in 2018, GARDP’s headquarters are located in Geneva, Switzerland.
GARDP North America Inc.
Established in the US in 2021, this 501c3 public charity organization aims to increase awareness, raise funds and advocate for policy change to counter AMR.
DNDi Latin america (Río de Janeiro)
This office supports GARDP’s work on institutional representation by liaising with pharmaceuticals, research partners, national governments and supranational organizations such as PAHO. It also supports access work.
DNDi GARDP Southern Africa
Established by DNDi and GARDP in 2018 for the implementation of GARDP’s trials in Southern Africa. The team also builds regional networks for advocacy, access and stewardship strategies for antibiotics, including SECURE.
DNDi eastern Africa (Nairobi)
This office assists with GARDP’s work in the region, including clinical trials and studies on neonatal sepsis and sexually transmitted infections.
DNDi South Asia (New Delhi)
This office is responsible for the implementation of GARDP’s activities, including observational studies and pharmaceutical drug development. It develops partnerships to adapt access and stewardship strategies for the regional context.
DNDi South-east Asia (Kuala Lumpur)
This office supports GARDP’s work in the region, including developing new, accessible STI treatments and expanding access to essential antibiotics via SECURE.
DNDi Japan (Tokyo)
This office helps GARDP liaise with Japanese pharmaceuticals, research partners and the Japanese government.
Representation in Australia
This representation links GARDP with companies and the Australian government.
-
GARDP Foundation
Set up as an independent not-for-profit in 2018, GARDP’s headquarters are located in Geneva, Switzerland.
-
GARDP North America Inc.
Established in the US in 2021, this 501c3 public charity organization aims to increase awareness, raise funds and advocate for policy change to counter AMR.
-
DNDi Latin america (Río de Janeiro)
This office supports GARDP’s work on institutional representation by liaising with pharmaceuticals, research partners, national governments and supranational organizations such as PAHO. It also supports access work.
-
DNDi GARDP Southern Africa
Established by DNDi and GARDP in 2018 for the implementation of GARDP’s trials in Southern Africa. The team also builds regional networks for advocacy, access and stewardship strategies for antibiotics, including SECURE.
-
DNDi eastern Africa (Nairobi)
This office assists with GARDP’s work in the region, including clinical trials and studies on neonatal sepsis and sexually transmitted infections.
-
DNDi South Asia (New Delhi)
This office is responsible for the implementation of GARDP’s activities, including observational studies and pharmaceutical drug development. It develops partnerships to adapt access and stewardship strategies for the regional context.
-
DNDi South-east Asia (Kuala Lumpur)
This office supports GARDP’s work in the region, including developing new, accessible STI treatments and expanding access to essential antibiotics via SECURE.
-
DNDi Japan (Tokyo)
This office helps GARDP liaise with Japanese pharmaceuticals, research partners and the Japanese government.
-
Representation in Australia
This representation links GARDP with companies and the Australian government.
Established by DNDi and GARDP in 2018, this independent organization is responsible for the implementation of GARDP’s trials in Southern Africa. The team also builds regional networks for advocacy, access and stewardship strategies for antibiotics, including SECURE.
GARDP is hosted in Japan by DNDi. This team liaises with Japanese pharmaceuticals, research partners and the Japanese government.
